Our scientific expertise spans the network of metabolic pathways that control the production of nucleic acids as well as the signal transduction pathways that allow cells to adapt to replication stress and DNA damage repair

Certain cancers are characterized by high levels of DNA replication stress due to increased signaling from oncogenic cells. This phenomenon renders such cancers significantly more susceptible than normal cells to therapies that constrain nucleotide biosynthesis. However, these therapies are often ineffective because of three mechanisms:

Intrinsic mechanisms that protect the genome against replication stress and damage

The ability of cancer cells to switch their nucleotide production to alternate biosynthetic pathways

Biological controls that rapidly adjust consumption to compensate for insufficient production

Identification of the key checkpoints that control these three resistance mechanisms has enabled the development of pharmacological agents that specifically intervene within these pathways.

Unlike many cancer drugs in development which are based on targeted inhibitors as single treatments, Trethera is adopting a fundamentally different approach: multi-target metabolic therapy. This approach enables precise inhibition of the pathways that cancer cells utilize to overcome single agent therapies. By using a co-targeting approach at the very beginning of treatment, the risks of drug resistance and/or poor response rates are minimized.